April 1, 12:00pm - 1:00pm
Mānoa Campus, Zoom ID: 423 437 1004 (See more information below and attached)

John A. Burns School of Medicine Department of Tropical Medicine & Pacific Center for Emerging Infectious Diseases Research Joint Seminar: "ERVEBO® - EBOLA ZAIRE VACCINE: A TALE OF INNOVATION AND COLLABORATION" by Beth-Ann Coller, Ph.D.

(Executive Director, Global Clinical Development, Merck Research Laboratories, North Wales, Pennsylvania) /

Abstract: Ebola continues to cause significant morbidity and mortality in regions of the world where the provision of healthcare and vaccine are difficult. The Merck vaccine is a live recombinant vesicular stomatitis virus (VSV) containing the Zaire Ebola virus glycoprotein (GP) in place of the VSV GP (rVSV<>G-ZEBOV-GP). Its safety, efficacy, or immunogenicity has been evaluated in 13 clinical trials, and the vaccine has been approved for use in humans by the European Medicines Agency, United States Food and Drug Administration, several African countries, and has been prequalified by the World Health Organization. More than 300,000 people have received the vaccine to date. Safety, immunogenicity, and efficacy data from across the program will be discussed as well as the use of the vaccine in the context of outbreak response.

Zoom Link: https://hawaii.zoom.us/j/4234371004

Call in: (669) 900-6833

Zoom ID: 423 437 1004


Event Sponsor
JABSOM Tropical Medicine/Pacific Center for Emerging Infectious Diseases Research, Mānoa Campus

More Information
Dr. Vivek Nerurkar, 808-692-1668, nerurkar@hawaii.edu

Share by email